Loading clinical trials...

Measuring Changes In Choroidal Thickness Induced By Prototype Soft Contact Lenses Worn For 1 Hour | Clinical Trials | Clareo Health

RECRUITINGNA

Measuring Changes In Choroidal Thickness Induced By Prototype Soft Contact Lenses Worn For 1 Hour

NCT07155551•Myoptechs, Inc

View on ClinicalTrials.gov

Summary

The objective of the study is to evaluate the short-term change in choroidal thickness induced by 3 prototype soft contact lenses for people with myopia.

Eligibility

Age

18 - 25 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Are 18-25 years of age (inclusive) and have full legal capacity to volunteer; Have read (or be read to) and signed the information and consent form; Habitually wear soft contact lenses or are spectacle wearers with previous experience of soft contact lens wear;
•Are myopic with both eyes having a vertex corrected spherical equivalent non-cycloplegic refraction of at least -0.50 DS and no more than -4.50 DS;
•Achieve at least LogMAR +0.10 with spherical equivalent refraction in each eye;
•Are willing and able to maintain the appointment schedule and follow the measurement visit instructions which include no use of caffeine drinks, alcohol or other stimulants 12 hours before each measurement visit and no smoking or use of recreational cannabis 24 hours before the study visit;
•Have not used a myopia control treatment within 2 years prior to Visit 0 (this includes multifocal spectacle or contact lens wear, orthokeratology, or atropine);
•Typically sleeps at least 7 hours per night.

Exclusion Criteria

•Participating in any concurrent clinical or research study;
•Have astigmatism of more than 1.00 DC in either eye as per non-cycloplegic refraction;
•Have amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency;
•Have any known active\* ocular disease and/or infection;
•Have a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism, and active allergies;
•Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include antihistamine, atropine eye drops;
•Have known sensitivity to the sodium fluorescein diagnostic pharmaceutical to be used in the study;
•Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment;
•Have undergone strabismus surgery, refractive error surgery or intraocular surgery;
•Are an employee of the Centre for Ocular Research \& Education directly involved in this study (i.e. on the delegation log).

Locations (1)

Centre for Ocular Research and Education at the School of Optometry and Vision Science at Waterloo University

Waterloo, Ontario, Canada

Key Dates

Start Date

August 25, 2025

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

September 4, 2025

Enrollment

ESTIMATED participants

Conditions

Myopia; Refractive Error

Interventions

Lens A

DEVICE

Lens B

DEVICE

Lens C

DEVICE

Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)

NCT06631339

MyopiaLight; Therapy, Complications+3 more

View study

RECRUITINGNA

The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.

NCT06882408

AmetropiaMyopia; Refractive Error+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions